



IPO RESEARCH REPORT

Sahajanand Medical Technologies Limited

Cardiovascular Device Maker in Turnaround — Rich Valuation, 100% Promoter/Investor Exit

IPO Open: Oct 15, 2026 IPO Close: Oct 19, 2026 Listing: Oct 23, 2026 (BSE, NSE)

OUR RECOMMENDATION

NEUTRAL*

*100% OFS; rich valuation vs. track record, rising borrowings

PRICE BAND

₹327 - ₹344

Lot: 43 shares | ₹14,792 min.

GMP (AS OF OCT 13, 2026)

₹35 (~10.2%)

Est. listing ₹379 | Unofficial

This report is a research summary for informational purposes only and does not constitute investment advice. GMP figures are unofficial grey-market indicators and may change materially before listing. Please read Section 13 (Disclaimer) before acting on this report.

1. IPO AT A GLANCE

Sahajanand Medical Technologies Limited (SMT) is a Surat, Gujarat-based, R&D-led manufacturer of Class III and Class C/D cardiovascular medical devices, spanning Vascular Intervention (coronary stents, PTCA balloons, drug-coated balloons) and Structural Heart (TAVI valves and occluders) product lines. The company is raising ₹475.48 crore entirely through an offer for sale (OFS) — there is no fresh issue, so the company itself will not receive any IPO proceeds. Selling shareholders include the promoters as well as investors Samara Capital Markets Holding, Kotak Pre-IPO Opportunities Fund and NHPEA Sparkle Holding BV. The issue opens on October 15, 2026 and closes on October 19, 2026, with listing on the BSE and NSE tentatively scheduled for October 23, 2026.

Issue Details

Particulars	Details
IPO Type	Mainboard — Book Built Issue
Issue Size	₹475.48 Cr (1,38,22,116 shares at upper band)
Fresh Issue	None — the company receives no IPO proceeds
Offer for Sale (OFS)	₹475.48 Cr (entire issue) by promoters & investors Samara Capital, Kotak Pre-IPO Opportunities Fund, NHPEA Sparkle Holding BV
Face Value	₹1 per share
Price Band	₹327 – ₹344 per share
Lot Size	43 shares
Minimum Retail Investment	₹14,792 (1 lot, upper band)
Anchor Investor Bidding	October 14, 2026
IPO Open Date	October 15, 2026
IPO Close Date	October 19, 2026
Basis of Allotment	October 21, 2026
Listing Date (Tentative)	October 23, 2026 on BSE & NSE
Market Cap at Upper Band	₹3,496.65 Cr (approx.)



Particulars	Details
Promoter Holding (Pre- / Post-Issue)	40.82% / 36.20%
Book Running Lead Managers	Motilal Oswal Investment Advisors & other merchant bankers (per RHP)
Registrar to the Issue	MUFG Intime India Pvt. Ltd.

Investors should confirm exact investor-category share-count cut-offs and the complete list of book running lead managers from the final RHP/bid-lot circular before applying.

2. COMPANY OVERVIEW

History & Incorporation

Sahajanand Medical Technologies Limited was founded in 2001 by Dhirajlal Kotadia, giving the company roughly a quarter-century of operating experience in cardiovascular medical devices. It is headquartered in Surat, Gujarat, and its cap table includes reputable institutional backers — Samara Capital, Morgan Stanley-linked entities and Kotak Investment Advisors — alongside well-known individual investor Ashish Kacholia.

Business Model

SMT designs, manufactures and markets technologically advanced Class III and Class C/D medical devices across two core areas: Vascular Intervention, comprising coronary stents, PTCA balloons and drug-coated balloons, and Structural Heart, comprising TAVI (transcatheter aortic valve implantation) valves and occluders. The company's flagship products, including the Supraflex Cruz drug-eluting stent and the Hydra balloon platform, are positioned by the company as providing a differentiated technical moat, supported by a global IP portfolio of 119 granted patents.

Scale & International Footprint

As of June 30, 2026, SMT had 1,605 full-time employees, along with 31 consultants and 707 contract-based employees. The company exports to 77 countries, reflecting a broad international distribution and regulatory-compliance footprint for a company of its scale, reducing dependence on the Indian market alone.

Key Shareholders

Shareholder Type	Details
Promoters	Founding promoter group; partial sellers in the OFS
Samara Capital Markets Holding	Institutional investor; selling shareholder in the OFS
Kotak Pre-IPO Opportunities Fund	Institutional investor; selling shareholder in the OFS
NHPEA Sparkle Holding BV	Institutional investor (linked to Morgan Stanley-affiliated private equity); selling shareholder in the OFS

Promoter shareholding is set to fall from approximately 40.82% pre-issue to approximately 36.20% post-issue — a relatively modest promoter stake even before this dilution, reflecting a cap table already significantly populated by financial/private-equity investors who are using this listing to partially exit.

3. ORDER BOOK / KEY OPERATING METRICS

For an R&D-led medical device manufacturer, patent portfolio depth, export reach, margin trajectory and balance-sheet trends are the key signals of both competitive durability and near-term financial health.

2001 Year Founded (~25 Years of Operating History)	119 Granted Global Patents	77 Countries Served via Exports	1,605 Full-Time Employees (+31 Consultants, 707 Contract, Jun 2026)
--	--------------------------------------	---	---



+18.1% FY26 Revenue Growth YoY	+174.7% FY26 PAT Growth YoY (Turnaround from FY24 Loss)	14.10% FY26 EBITDA Margin (up from 12.21% in FY24)	10.60% FY26 Return on Net Worth (RoNW)
1.12x Net Debt / EBITDA, FY26 (up from 0.86x in FY24)	₹320.63 Cr Total Borrowings (as of Jun 2026, still rising)	40.82% → 36.20% Promoter Holding, Pre- vs Post- Issue	₹3,496.65 Cr Post-Issue Market Cap at Upper Band

Source: RHP; company disclosures via Abhinav Mishra's Substack, Flattrade Kosh, Chittorgarh, Chanakyanipothi and Multibagg.



4. FINANCIAL PERFORMANCE

3-Year Financial Snapshot (₹ in Crore, restated consolidated)

Particulars	FY24	FY25	FY26	CAGR / YoY
Revenue from Operations	901.60	1,024.88	1,210.50	15.9% CAGR; +18.1% YoY (FY26)
Total Income	908.59	1,035.96	1,218.73	+17.6% YoY (FY26)
EBITDA	110.05	128.02	170.66	+33.3% YoY (FY26)
EBITDA Margin (%)	12.21	12.49	14.10	Improving
Profit After Tax (PAT)	-7.35 (loss)	25.15	69.08	+174.7% YoY (FY26)
PAT Margin (%)	-0.82	2.45	5.71	Turnaround, improving
Return on Equity (RoE)	-2.34	3.68	10.35	Turnaround, improving
Return on Net Worth (RoNW)	n.a.	n.a.	10.60	—
Net Worth	526.30	545.23	616.05	+13.0% YoY (FY26)
Total Borrowings	n.a.	224.96	269.53	+19.8% YoY (FY26)
Net Debt / EBITDA (x)	0.86	0.91	1.12	Rising

Q1 FY27 (Apr–Jun 2026): total income ₹354.33 Cr, PAT ₹15.09 Cr, EBITDA ₹48.58 Cr, EBITDA margin 13.81%, PAT margin 4.29% (below FY26's 5.71%), net worth ₹631.72 Cr, total borrowings ₹320.63 Cr (continuing to rise). Quarterly (non-annualised) return ratios for Q1 FY27 were RoE 2.07%, RoNW 2.31% and RoCE 3.16%, which are naturally lower than full-year FY26 figures and not directly comparable to them.

Analyst Notes on Financial Trends

- **A genuine, credible turnaround — but a short one:** SMT moved from a net loss of ₹7.35 Cr in FY24 to PAT of ₹69.08 Cr in FY26, with EBITDA margin improving from 12.21% to 14.10% over the same period. This is a real operational inflection, but it means the company has only two consecutive years of profitability (FY25 and FY26) to its name — a materially shorter track record than some other issues we have reviewed recently.
- **Borrowings are rising, not falling, even as profit improves:** Total borrowings grew from ₹224.96 Cr (FY25) to ₹269.53 Cr (FY26) and further to ₹320.63 Cr (June 2026), with Net Debt/EBITDA climbing from 0.86x (FY24) to 1.12x (FY26) — the opposite of the deleveraging trend seen in several other recently reviewed issues.
- **The most recent quarter shows a sequential dip, not a continuation of FY26's pace:** Q1 FY27 PAT margin (4.29%) came in below FY26's full-year 5.71%, and quarterly return ratios, while not directly comparable to annualised figures, point to a business that has not yet demonstrated it can sustain FY26's improved trajectory into the new fiscal year.
- **Because this is a 100% OFS, none of this growth is being funded by fresh primary capital:** Unlike some peer issues that use IPO proceeds to fund capacity expansion or debt reduction, SMT's rising borrowings and growth plans will need to be funded from internal accruals or future financing, independent of this listing.

Figures sourced from RHP-based summaries (Abhinav Mishra's Substack, Flattrade Kosh, Chittorgarh, Chanakyanipothi, Multibagg) which are broadly consistent with one another. Older, pre-restatement figures circulating from sources dated more than a year ago (citing materially different FY24/FY25 revenue and PAT figures) appear stale and have been excluded from this analysis. Investors should cross-check exact line items against the final RHP financial statements before investing.

5. VALUATION ANALYSIS



Metric	Value
EPS — Pre-Issue (₹, FY26 basis)	6.67 – 6.80
EPS — Post-Issue (₹, annualised Q1 FY27 basis)	5.94 – 6.48
P/E (x) — Pre-Issue, on FY26 earnings, upper band	50.59 – 51.57
P/E (x) — Post-Issue, on annualised Q1 FY27 earnings, upper band	57.91 – 57.94
NAV / Share (₹)	62.76 (Mar 2026) – 64.35 (Jun 2026)
Price / Book Value (x)	5.48
Market Cap at Upper Band (₹ Cr)	3,496.65

Exact EPS and P/E figures vary modestly across trackers (e.g. EPS cited as both ₹6.67 basic / ₹6.48 diluted in one source, and ₹6.80 pre-issue / ₹5.94 post-issue in another, with the latter annualising Q1 FY27 earnings). Multiple independent reviewers explicitly flag this valuation as rich: one notes the ~50.6x FY26 P/E “demands sustained execution” and that “rising borrowings and modest profitability reduce valuation comfort,” while another recommends evaluating the issue “with moderate expectations given its full valuation.”

Peer Valuation Context

The RHP names Poly Medicure Limited and Laxmi Dental Limited as listed peers. At approximately 51.4x–51.57x FY26 P/E, SMT is priced essentially in line with Poly Medicure (51.40x) — a considerably larger, more established and longer-profitable medical device company — and at a clear premium to Laxmi Dental (36.35x), despite Laxmi Dental posting a higher RoNW (11.91% vs. SMT's 10.60%). In other words, the market is not offering investors a valuation discount for SMT's shorter profitability track record, rising leverage, or relatively lower capital efficiency versus at least one of its two named peers.

Company	P/E (x)	NAV/Share (₹)	RoNW (%)
Sahajanand Medical Technologies Limited (self)	51.40–51.57	62.76	10.60
Poly Medicure Limited	51.40	306.40	10.37
Laxmi Dental Limited	36.35	44.27	11.91

Peer P/E figures as given in the RHP, based on BSE closing prices as of October 6, 2026 and FY26 diluted EPS. Neither peer is an exact business-mix match for SMT's cardiovascular-specific product portfolio, so the comparison is indicative only.

6. USE OF ISSUE PROCEEDS

Because this IPO is entirely an offer for sale, Sahajanand Medical Technologies Limited will not receive any proceeds from the issue — the full ₹475.48 crore raised goes directly to the selling shareholders: the promoters and institutional investors Samara Capital Markets Holding, Kotak Pre-IPO Opportunities Fund and NHPEA Sparkle Holding BV. Unlike HD Fire Protect's similarly structured 100% OFS — where the company was debt-free with ample surplus cash and arguably had limited need for primary capital — SMT's own borrowings have been rising (from ₹224.96 Cr in FY25 to ₹320.63 Cr as of June 2026), making the absence of any fresh capital in this raise a more notable consideration for investors evaluating the company's near-term funding and deleveraging needs.

No funds from this IPO will be used for capital expenditure, debt repayment, R&D investment or working capital at the company level, since there is no fresh issue component.

7. INDUSTRY OVERVIEW & TAILWINDS

- **Rising global cardiovascular disease burden:** Continued growth in cardiovascular disease incidence, both in India and globally, supports sustained demand for coronary stents, balloon catheters and structural heart intervention devices.
- **Growing adoption of structural heart interventions:** Increasing clinical adoption of less-invasive structural heart procedures, including TAVI, represents an expanding addressable market beyond the company's traditional vascular intervention base.



- **India as a growing hub for medical device manufacturing and exports:** Government and industry initiatives supporting domestic medical device manufacturing, combined with SMT's existing 77-country export footprint, position the company to benefit from continued growth in India-manufactured device exports.
- **R&D and patent-driven differentiation:** A portfolio of 119 granted global patents and continued R&D investment support the company's ability to compete on clinical differentiation rather than price alone, in a category where regulatory and quality barriers are significant.

8. KEY STRENGTHS

- **Genuine financial turnaround:** PAT swung from a loss of ₹7.35 Cr in FY24 to ₹69.08 Cr in FY26, with EBITDA margin improving from 12.21% to 14.10% over the same period — a credible operational inflection.
- **Specialised, R&D-led product portfolio:** Differentiated offerings across Vascular Intervention and Structural Heart categories, anchored by flagship products such as Supraflex Cruz and Hydra.
- **Strong intellectual property moat:** 119 granted global patents support a defensible technical position in a regulation-heavy, innovation-dependent industry.
- **Broad international footprint:** Exports to 77 countries reduce dependence on the Indian market and demonstrate an ability to navigate diverse international regulatory regimes.
- **Reputable institutional backing:** Samara Capital, Morgan Stanley-linked entities, Kotak Investment Advisors and well-known investor Ashish Kacholia lend credibility to the company's governance and growth trajectory.
- **Improving, if still-developing, return ratios:** RoE improved from -2.34% (FY24) to 10.35% (FY26), evidencing a genuine, if recent, improvement in capital efficiency.
- **Established operating history:** Founded in 2001, giving the company roughly a quarter-century of experience in a technically demanding medical device category.



9. KEY RISKS & CONCERNS

We flag the following risk factors, colour-coded by our assessment of relative severity. Investors should also review the detailed “Risk Factors” section of the RHP for the complete and legally exhaustive list of risks disclosed by the Company.

Risk Factor	Description	Severity
100% offer-for-sale — company receives zero proceeds	This IPO is purely a liquidity event for the promoters and financial investors (Samara Capital, Kotak Pre-IPO Opportunities Fund, NHPEA Sparkle Holding BV); none of the ₹475.48 Cr raised supports the company's own balance sheet, capex or deleveraging, even as its own borrowings have been rising.	HIGH
Rich valuation with little comfort versus peers	At ~50.6–58x P/E, SMT is priced essentially in line with the much larger, longer-profitable Poly Medicure (51.40x) and at a clear premium to Laxmi Dental (36.35x) despite Laxmi Dental's higher RoNW; multiple independent reviewers explicitly describe this as leaving “limited room for earnings disappointment” and reduced “valuation comfort.”	HIGH
Very short, recent profitability track record	The company reported a net loss as recently as FY24 (₹7.35 Cr); sustained profitability spans only two fiscal years (FY25–FY26), a materially shorter track record than several other recently reviewed issues.	HIGH
Rising borrowings alongside improving profit	Total borrowings grew from ₹224.96 Cr (FY25) to ₹269.53 Cr (FY26) to ₹320.63 Cr (June 2026), with Net Debt/EBITDA climbing from 0.86x to 1.12x — an increasing, not improving, leverage trend.	MEDIUM
Sequential softening in the latest quarter	Q1 FY27 PAT margin (4.29%) came in below FY26's full-year level (5.71%), and quarterly return ratios point to a business that has not yet demonstrated it can sustain FY26's improved trajectory into the new fiscal year.	MEDIUM
Already-modest and further-declining promoter holding	Promoter holding falls from 40.82% pre-issue to 36.20% post-issue — a cap table already significantly populated by financial investors, several of whom are partially exiting through this OFS.	MEDIUM
Regulatory and product-liability risk inherent to Class III devices	Cardiovascular implants carry significant regulatory, quality-control and liability risk across the 77 countries the company exports to, with any adverse regulatory or clinical event potentially having an outsized impact on the business.	MEDIUM
Mildly softening grey-market sentiment into the open	GMP eased modestly from ₹40 (Oct 12, 2026) to ₹35 (Oct 13, 2026) in the days just before opening — a smaller decline than seen in some other recent issues, but still a signal worth monitoring.	LOW

10. IPO TIMELINE & HOW TO APPLY

Event	Date
Anchor Investor Bidding	October 14, 2026
IPO Opens	October 15, 2026
IPO Closes	October 19, 2026
Basis of Allotment (Tentative)	October 21, 2026
Refund / Demat Credit (Tentative)	October 22, 2026
Listing Date (Tentative)	October 23, 2026 (BSE, NSE)



How to Apply – ASBA / UPI

- Apply through your bank's ASBA facility (net-banking) or a broker/app supporting UPI-based bidding; funds are blocked in your account, not debited, until allotment.
- Select “Sahajanand Medical Technologies Limited” IPO, choose the retail category if applying as an individual, and bid at the cut-off price or within the ₹327–₹344 band.
- Minimum retail application is 1 lot of 43 shares (≈₹14,792 at the upper band).
- Approve the UPI mandate request promptly (within the specified window) to ensure your bid is registered before the issue closes.
- Track allotment status via the registrar, MUFG Intime India Pvt. Ltd., using your PAN, application number or demat details after the basis-of-allotment date.

11. GMP & INVESTOR SENTIMENT

Metric	Value
Grey Market Premium (as of Oct 13, 2026)	₹35 (~10.2% over upper band)
Grey Market Premium — Oct 12, 2026	₹40 (~11.9% over upper band)
Implied Listing Price Estimate	≈₹379–384 (vs. ₹344 issue price)

GMP has eased modestly from ₹40 to ₹35 in the two most recent sessions tracked ahead of the issue's opening, implying a still-positive but slightly softening double-digit percentage listing gain. This decline is more modest in magnitude than seen in some other recently reviewed issues, suggesting broadly steady, if not especially enthusiastic, grey-market sentiment heading into subscription. Investors should track GMP and category-wise subscription (QIB, NII, retail) through the bidding window, as sentiment can shift meaningfully before listing.

GMP (Grey Market Premium) is an informal, unregulated indicator quoted in the unofficial “grey market” and is not published or endorsed by any stock exchange, SEBI, or Ganesh StockInvest. It reflects prevailing sentiment at a point in time, can swing sharply — including turning negative — right up to the listing date, and should never be the sole basis for an investment decision. Actual listing price performance may differ materially from GMP-implied levels.



12. GANESH STOCKINVEST RECOMMENDATION

GANESH STOCKINVEST RECOMMENDATION: NEUTRAL — SELECTIVE, LONG-TERM ONLY

Credible turnaround and institutional backing, but rich valuation, rising debt and a 100% exit structure warrant caution

Investment Rationale

- **Genuine operational turnaround:** A swing from a net loss in FY24 to meaningfully improving profitability by FY26, with EBITDA margin expansion alongside it, reflects real business improvement rather than a purely accounting-driven shift.
- **Differentiated, R&D-led positioning:** A 119-patent global IP portfolio and specialised cardiovascular device portfolio support a genuine competitive moat in a technically demanding category.
- **Credible institutional backing:** Samara Capital, Morgan Stanley-linked entities and Kotak Investment Advisors, alongside marquee investor Ashish Kacholia, lend some governance and strategic credibility to the company.

Caution Factors

- This is a 100% offer-for-sale — the company receives no capital from this IPO, even as its own borrowings continue to rise, a materially different and arguably less favourable setup than other recently reviewed 100%-OFS issues.
- At ~50.6–58x P/E, the valuation is rich and, critically, is not offered at a discount to peers: SMT trades essentially in line with the larger, longer-profitable Poly Medicure and at a premium to Laxmi Dental despite Laxmi Dental's higher RoNW.
- The company's profitability track record spans only two fiscal years (FY25–FY26), following a loss as recently as FY24 — a shorter and less-proven history than the valuation multiple would typically command.
- Borrowings have risen steadily (FY25 to June 2026), and the most recent quarter (Q1 FY27) showed a sequential dip in PAT margin versus the full FY26 year — both signals that the improved FY26 trajectory is not yet fully confirmed as durable.
- Promoter holding, already modest at 40.82% pre-issue, falls further to 36.20% post-issue, reflecting a cap table substantially driven by financial investors partially exiting through this listing.

Suitability – Target Investor Types

Investor Profile	Suitability
Retail investors seeking listing-day gains	Suitable with caution — a modest, still-positive GMP suggests some listing-day demand, though sentiment has softened slightly into the open
Long-term, growth-oriented equity investors	Suitable with caution — acceptable only if comfortable that the FY26 turnaround proves durable despite rising debt and a sequentially softer Q1 FY27, and that the rich valuation leaves room to grow into rather than correct from
Conservative / risk-averse investors	Less suitable — a short profitability track record, rising leverage and a rich, peer-premium valuation sit outside a conservative risk tolerance
Institutional / QIB investors with sector expertise	Suitable with caution — best positioned to independently assess whether SMT's R&D pipeline and patent portfolio justify a valuation in line with larger, more established peers

Overall View: Sahajanand Medical Technologies presents a genuinely credible financial turnaround story, backed by reputable institutional investors and anchored in a differentiated, patent-protected cardiovascular device portfolio. However, this is a 100% offer-for-sale that delivers no capital to a company whose own borrowings have been rising, not falling; the valuation, at roughly 50–58x earnings, is priced essentially in line with (or at a premium to) its closest listed



peers despite a much shorter profitability history; and the most recent quarter showed signs of the FY26 improvement softening rather than accelerating. This combination — unlike HD Fire Protect's similarly structured but materially stronger 100%-OFS profile — does not offer the valuation cushion or balance-sheet strength to support an unqualified Subscribe. We rate this issue NEUTRAL, selective and long-term-oriented only, suitable for investors who have specifically weighed the rich valuation and rising leverage against the credibility of the turnaround.



13. DISCLAIMER

This report has been prepared by Ganesh StockInvest, a SEBI-registered stock broking and research entity, for informational purposes only and is intended solely for the use of the recipient. It does not constitute, and should not be construed as, an offer, solicitation, invitation or recommendation to buy or sell any securities, including the equity shares of Sahajanand Medical Technologies Limited discussed herein.

The information, opinions, and estimates contained in this report have been compiled from the Company's Red Herring Prospectus (RHP), stock exchange disclosures, and other publicly available sources believed to be reliable as of the date of publication. However, Ganesh StockInvest makes no representation or warranty, express or implied, as to the accuracy, completeness, or reliability of such information, and shall not be held liable for any loss arising from the use of this report.

Grey Market Premium (GMP) figures cited in this report are unofficial, unregulated indicators sourced from third-party grey-market trackers. They are not endorsed by SEBI, any stock exchange, or Ganesh StockInvest, are subject to change without notice, and must not be relied upon as a predictor of actual listing performance.

Investments in the securities market, including IPOs, are subject to market risks. Past performance, growth rates, or return ratios are not indicative of future results. Prospective investors are strongly advised to read the Company's RHP in its entirety, including the "Risk Factors" section, and to consult their own financial, legal and tax advisors before making any investment decision. The recommendation in this report reflects the views of Ganesh StockInvest's research desk as of the date of publication and is subject to change without prior notice.

Ganesh StockInvest, its analysts, and/or their associates may or may not hold positions in the securities discussed in this report. This document may not be reproduced, redistributed, or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose, without the prior written consent of Ganesh StockInvest.

GANESH STOCKINVEST | SEBI-Registered Research Analyst | This report is for private circulation and informational purposes only — not investment advice.